Mechanisms of childhood obesity underlying the susceptibility to multisystem inflammatory syndrome in children (MIS-C)

儿童肥胖导致儿童多系统炎症综合征易感性的机制（MIS-C）

• 批准号: 10450145
• 负责人: Janet Chou
• 金额: $ 44.25万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10450145
• 关键词: 12 year old; 2019-nCoV; Accounting; Acute; Adult; Autoimmune Diseases; Biological; Biological Markers; Blood Coagulation Disorders; Body mass index; Body measure procedure; COVID-19; COVID-19 detection; COVID-19 test; COVID-19 vaccine; Cells; Child; Childhood; Clinic; Collaborations; Communities; Complication; Coronary Aneurysm; Data; Data Analyses; Data Set; Development; Disease; Education; Endocrinology; Equilibrium; Europe; Exanthema; Exhibits; Fever; Functional disorder; Genetic Polymorphism; Genetic Risk; Genetic Screening; Genetic study; Goals; Hematological Disease; Immune; Immune response; Immunity; Infection; Inflammation; Inflammatory; Inflammatory Response; Interferons; Lymphopenia; Mediating; Metabolism; Multiomic Data; Multisystem Inflammatory Syndrome in Children; Myocardial dysfunction; Obesity; Only Child; Overweight; Patients; Phase; Population; Predisposition; Prevalence; Public Health; Pulmonary Heart Disease; Research Personnel; Risk; Risk Assessment; Risk Factors; SARS-CoV-2 infection; Sampling; Severities; Shock; Signal Transduction; Symptoms; Syndrome; T-Cell Activation; T-Lymphocyte; Testing; United States; Vaccine Clinical Trial; Variant; Viral; Virus; Virus Diseases; Weight; acute infection; cohort; comorbidity; cytopenia; disorder risk; gastrointestinal symptom; genetic risk factor; genetic variant; immune activation; insight; multiple omics; obesity genetics; obesity in children; overweight child; post SARS-CoV-2 infection; severe COVID-19

PROJECT SUMMARY/ABSTRACT Unpredictability is the hallmark of Multisystem Inflammatory Syndrome in Children (MIS-C). MIS-C is a severe pediatric complication of SARS-CoV-2 infection. MIS-C is distinct from COVID-19. It is not associated with pre-existing cardiopulmonary, autoimmune, or hematologic disorders. It can occur either during acute phase with detectable SARS-CoV-2 virus, or in the post-infectious period of several weeks after acute infection. Milder symptoms of MIS-C include fevers, rashes, and gastrointestinal symptoms, but can progress to cytopenias, coagulopathy, myocardial dysfunction, coronary aneurysms, and/or shock. We and others have found that MIS- C is associated with pediatric overweight and obesity, thereby identifying over 380 million children at risk for this disease. The mechanisms by which overweight and obesity influence the development of MIS-C are unknown. Until a vaccine against SARS-CoV-2 is globally available to all children, they will remain vulnerable to MIS-C. Our preliminary studies indicate that MIS-C is a highly inflammatory disease that incites more severe immune cell activation than COVID-19, particularly in overweight and obese children. Overweight and obese children with MIS-C had more T cell lymphopenia and T cell activation than their normal weight counterparts, suggesting an increased risk for more severe disease. Deleterious genetic variants increasing IFN and inflammatory signaling were exclusively found in patients with MIS-C, rather than severe COVID-19. This is a mechanistic counterpoint to defective IFN signaling associated with severe COVID-19 in adults. Our central hypothesis is that pediatric overweight and obesity prime interferon signaling, thereby increasing T cell activation and ultimately, the risk of MIS-C Aim 1 will elucidate how pediatric overweight and obesity drive immune cell dysfunction during MIS-C. The proposed studies will test the hypotheses that pediatric overweight and obesity are associated with more severe MIS-C, characterized by excessive interferon signaling and T cell activation. Aim 2 will identify mechanistic risk factors for MIS-C. The proposed studies will test the hypothesis that, even in the absence of infection, circulating immune cells from overweight and obese children exhibit an increased interferon signature that promotes T cell activation. We will develop a strategy for stratifying MIS-C by integrating genetic screening with measures of body mass index. Building on collaborations spanning over a decade and unique cohorts of children with MIS-C and/or obesity, our investigator team brings expertise in MIS-C, host immunity, pediatric obesity and endocrinology, and multiomics. This project will generate causal insights of how overweight and obesity influence the development and severity of MIS-C, with the goal of developing strategies for a population that remains at risk for this disease.

项目摘要/摘要 不可预测性是儿童多系统炎症综合征（MIS-C）的标志。MIS-C是一个 SARS-CoV-2感染的严重儿科并发症。MIS-C与COVID-19不同。它与 有心肺、自身免疫或血液疾病的患者。它可以发生在急性期， 可检测到SARS-CoV-2病毒，或在急性感染后数周的感染后阶段。温和 MIS-C的症状包括发热、皮疹和胃肠道症状，但可进展为血细胞减少， 凝血病、心肌功能障碍、冠状动脉瘤和/或休克。我们和其他人发现- C与儿童超重和肥胖有关，因此确定了超过3.8亿儿童有此风险 疾病超重和肥胖影响MIS-C发展的机制尚不清楚。 在全球所有儿童都能获得针对SARS-CoV-2的疫苗之前，他们仍将容易感染MIS-C。 我们的初步研究表明，MIS-C是一种高度炎症性疾病， 免疫细胞激活比COVID-19更快，特别是在超重和肥胖儿童中。超重和肥胖 患有MIS-C的儿童比正常体重的儿童有更多的T细胞淋巴细胞减少和T细胞活化， 表明患更严重疾病的风险增加。有害的遗传变异增加IFN和 炎症信号仅在MIS-C患者中发现，而不是严重的COVID-19。这是一 与成人中严重COVID-19相关的缺陷IFN信号传导的机械对应。我们的中央 一种假说认为，儿童超重和肥胖引发干扰素信号传导，从而增加T细胞 激活并最终导致MIS-C风险 目的1将阐明儿童超重和肥胖如何在MIS-C期间驱动免疫细胞功能障碍。 这项研究将验证儿童超重和肥胖与更多的 严重MIS-C，其特征在于过度的干扰素信号传导和T细胞活化。 目标2将确定MIS-C的机械风险因素。拟议中的研究将检验这一假设， 即使在没有感染的情况下，来自超重和肥胖儿童的循环免疫细胞也表现出 增加干扰素信号，促进T细胞活化。我们将制定一项战略，通过以下方式对MIS-C进行分层 将遗传筛查与体重指数测量相结合。 基于十多年的合作和MIS-C和/或肥胖儿童的独特队列， 我们的研究团队带来了MIS-C、宿主免疫、儿童肥胖和内分泌学方面的专业知识， 多组学。该项目将产生超重和肥胖如何影响发展的因果见解， 和严重程度的MIS-C，目标是制定战略，人口仍然处于这种疾病的风险。